LBPS Key Statistics, Chart & Performance
The current stock price of LBPS is 1.65 null. In the past month the price decreased by -50%. In the past year, price decreased by -84.79%.
LBPS Technical Analysis
LBPS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LBPS. LBPS may be in some trouble as it scores bad on both profitability and health.
LBPS Financial Highlights
Over the last trailing twelve months LBPS reported a non-GAAP Earnings per Share(EPS) of -3.24. The EPS decreased by -43.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -10376.92% | ||
| ROA | -125.66% | ||
| ROE | N/A | ||
| Debt/Equity | 0.42 |
LBPS Forecast & Estimates
6 analysts have analysed LBPS and the average price target is 7.52 null. This implies a price increase of 356.04% is expected in the next year compared to the current price of 1.65.
LBPS Ownership
About LBPS
Company Profile
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. The firm is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The firm's LBPs are biologics based on live organisms, namely single strains of bacteria. The company has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.
Company Info
4D Pharma PLC
9 Bond Court
LEEDS LS1 2JZ GB
CEO: Duncan Peyton
Employees: 95
Phone: 441138950130.0
4D Pharma PLC / LBPS FAQ
What does 4D Pharma PLC do?
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. The firm is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The firm's LBPs are biologics based on live organisms, namely single strains of bacteria. The company has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.
Can you provide the latest stock price for 4D Pharma PLC?
The current stock price of LBPS is 1.65 null. The price increased by 2.48% in the last trading session.
What is the dividend status of 4D Pharma PLC?
LBPS does not pay a dividend.
What is the ChartMill rating of 4D Pharma PLC stock?
LBPS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy LBPS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LBPS.
What is the market capitalization of LBPS stock?
4D Pharma PLC (LBPS) has a market capitalization of 37.19M null. This makes LBPS a Nano Cap stock.